Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2024-11-13 Director's Dealing
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 100% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, reporting a transaction by a Person Discharging Managerial Responsibilities (PDMR), specifically a purchase of ordinary shares by a senior independent Non-Executive Director. The content focuses on insider shareholding transactions, detailing the nature, quantity, price, and date of the transaction. There is no financial performance data, earnings information, or management discussion. The document is short (4413 characters) and is a regulatory disclosure of insider share transactions. This fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades).
2024-11-13 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official announcement from AstraZeneca PLC, identified by the 'RNS Number' (1405M) and the explicit mention of RNS being the news service of the London Stock Exchange. The content details a 'Transaction by Person Discharging Managerial Responsibilities' (PDMR), specifically a purchase of ordinary shares by a Non-Executive Director (Philip Broadley). This type of insider transaction report is specifically covered by the 'Director's Dealing' definition. Although it is distributed via RNS, the specific nature of the filing points directly to DIRS rather than the general RNS fallback.
2024-11-13 English
ASTRAZENECA INVESTS $3.5 BILLION IN US
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content primarily announces a $3.5 billion investment in the US for R&D and manufacturing expansion. It includes no financial statements or detailed financial analysis but is an announcement of a capital investment and strategic update. The document length is 4326 characters, which is relatively short and reads like a press release or announcement rather than a full financial report. It does not contain quarterly or annual financial results, nor does it provide detailed management discussion or audit information. Given the nature of the content—an update on capital investment and expansion plans—the most appropriate classification is Capital/Financing Update (CAP).
2024-11-12 English
KOMET PHASE III TRIAL MET PRIMARY ENDPOINT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the KOMET Phase III trial results meeting the primary endpoint, including clinical trial data, safety profile, and strategic collaboration details. The document is not an annual or quarterly report, nor is it a transcript, proxy, or voting result announcement. It is a regulatory filing used to disclose material information to the SEC and investors. The length and content indicate it is a comprehensive disclosure but not a full financial report like a 10-K or 10-Q. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2024-11-12 English
9M AND Q3 2024 RESULTS
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer submitted to the SEC. It contains detailed financial results for the nine months and third quarter of 2024, including revenue, EPS, segment performance, guidance updates, and pipeline highlights. The presence of comprehensive financial data, management commentary, and forward-looking guidance indicates this is an interim or quarterly financial report rather than a brief announcement or certification. The document is about 15,000 characters long, which supports it being a substantive report. Form 6-K filings often serve as interim reports for foreign issuers. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2024-11-12 English
DATO-DXD NEW BLA SUBMITTED, NSQ BLA WITHDRAWN
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, submitted to the SEC as a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the submission and withdrawal of Biologics License Applications (BLAs) for a drug candidate, datopotamab deruxtecan, including clinical trial data and regulatory interactions with the FDA. The document is not an annual or quarterly financial report, nor is it a transcript, audit, or management report. It is a regulatory filing providing material information about drug development and regulatory status updates. Form 6-K filings are typically classified under Regulatory Filings (RNS) as they are miscellaneous reports submitted by foreign issuers to keep the market informed of material events. The document length (15,000 characters) and content confirm it is a substantive regulatory announcement rather than a brief report publication announcement or certification. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-11-12 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.